Pancreatic Cancer Research

ResearcherFred and Pamela Buffett Cancer CenterActive in the last 2 years

Amarnath (Amar) Natarajan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5067-0203; OpenAlex author ID A5033239597; NIH RePORTER profile ID 8482455. Sources: OpenAlex.

Their work

Papers
6 (first author 0, last author 3)
Trials
0
Grants
3
Labs led
2
Collaborators
34
Papers, trials and grants by year

2015: 1 grant · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: 1 grant · 2021: 2 papers · 2022: 1 paper · 2023: none · 2024: 2 papers · 2025: none · 2026: 1 grant

Papers 6

  1. Cancer-associated fibroblast-derived acetate promotes pancreatic cancer development by altering polyamine metabolism via the ACSS2-SP1-SAT1 axis. Co-author DOI 10.1038/s41556-024-01372-4↗
  2. Author Correction: Cancer-associated fibroblast-derived acetate promotes pancreatic cancer development by altering polyamine metabolism via the ACSS2-SP1-SAT1 … Co-author DOI 10.1038/s41556-024-01417-8↗
  3. The human AP-endonuclease 1 (APE1) is a DNA G-quadruplex structure binding protein and regulates KRAS expression in pancreatic ductal adenocarcinoma cells. Co-author DOI 10.1093/nar/gkac172↗
  4. Aminopyrazole based CDK9 PROTAC sensitizes pancreatic cancer cells to venetoclax. Last author DOI 10.1016/j.bmcl.2021.128061↗
  5. Structure activity relationship (SAR) study identifies a quinoxaline urea analog that modulates IKKβ phosphorylation for pancreatic cancer therapy. Last author DOI 10.1016/j.ejmech.2021.113579↗
  6. CDK5 Inhibitor Downregulates Mcl-1 and Sensitizes Pancreatic Cancer Cell Lines to Navitoclax. Last author DOI 10.1124/mol.119.116855↗

Grants 3

  1. Development of Quinoxaline Based IKKbeta Inhibitors for Kras Driven Cancers R01CA197999↗
  2. PROTACs for pancreatic cancer therapy R21CA251151↗
  3. Phosphorylated Form of Activated IKKbeta and Pancreatic Cancer R21CA182820↗

Closest collaborators

The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Pankaj Kumar Singh · 3 shared papers, 2022–2024 · strength 0.43
  2. Michael Anthony Hollingsworth · 3 shared papers, 2019–2024 · strength 0.36
  3. Kamiya Mehla · 2 shared papers, 2024 · strength 0.28
  4. Rosa F. Hwang · 2 shared papers, 2024 · strength 0.28
  5. Ajay Jain · 2 shared papers, 2024 · strength 0.28
  6. Vikrant Rai · 2 shared papers, 2024 · strength 0.28
  7. Divya Murthy · 2 shared papers, 2024 · strength 0.28
  8. Tuo Hu · 2 shared papers, 2024 · strength 0.28
  9. Aneesha Dasgupta · 2 shared papers, 2024 · strength 0.28
  10. Chunbo He · 2 shared papers, 2024 · strength 0.28
  11. Robert Powers · 2 shared papers, 2024 · strength 0.28
  12. Teklab Gebregiworgis · 2 shared papers, 2024 · strength 0.28
  13. Nina V. Chaika · 2 shared papers, 2024 · strength 0.28
  14. Scott E. Mulder · 2 shared papers, 2024 · strength 0.28
  15. Joshua J. Souchek · 2 shared papers, 2024 · strength 0.28
  16. Sai Sundeep Kollala · 2 shared papers, 2024 · strength 0.28
  17. Barish H. Edil · 2 shared papers, 2024 · strength 0.28
  18. Ryan J. King · 2 shared papers, 2024 · strength 0.28
  19. Ravi Kumar Thakur · 2 shared papers, 2024 · strength 0.28
  20. Kathryn Elaine Wellen · 2 shared papers, 2024 · strength 0.28
  21. Paul M. Grandgenett · 2 shared papers, 2024 · strength 0.28
  22. Surendra Kumar Shukla · 2 shared papers, 2024 · strength 0.28
  23. Susanna Varkey Ulahannan · 2 shared papers, 2024 · strength 0.28
  24. Kuldeep Singh Attri · 2 shared papers, 2024 · strength 0.28
  25. Hannah M. King · 2 shared papers, 2019–2021 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.